CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope

Détails

ID Serval
serval:BIB_4197B019D7E6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope
Périodique
Vaccine
Auteur⸱e⸱s
Cornet  S., Menez-Jamet  J., Lemonnier  F., Kosmatopoulos  K., Miconnet  I.
ISSN
0264-410X (Print)
Statut éditorial
Publié
Date de publication
03/2006
Volume
24
Numéro
11
Pages
1880-8
Notes
Comparative Study
Journal Article --- Old month value: Mar 10
Résumé
The use of synthetic peptides derived from tumor-associated Ags is attractive for the development of antitumoral vaccines as far as strong adjuvants are found to render them immunogenic. Here, we investigated the possibility to enhance the CD8 response against the human and mouse shared TERT(572Y) HLA-A*0201 restricted modified cryptic peptide by using ODN-CpG as adjuvant. Humanized transgenic mice were immunized with the TERT(572Y) modified cryptic peptide in the presence of ODN-CpG and compared to mice immunized in IFA. By contrast with IFA, we first showed that, in vivo, ODN-CpG leads to the recruitment of dendritic cells in the lymph nodes draining the injection site. Those cells and especially the CD11c+ CD11b- CD8a+ lymphoid and the CD11c+ B220+ plasmacytoid dendritic cells were activated as shown by up-regulation of CD40 at their cell surface. Immunization against TERT(572Y) peptide in the presence of ODN-CpG rather than IFA led to a strong CD8 response and can delayed mortality in an induced tumor model. Study of the CD8 response obtained after antigenic challenge suggested that a functional memory response is induced upon vaccination with ODN-CpG. Thus, MHC class I-restricted epitope in combination of ODN-CpG is a promising and rather simple cancer vaccine formulation.
Mots-clé
Adjuvants, Immunologic/administration & dosage Animals Antigen-Presenting Cells Antigens, CD40/analysis CD8-Positive T-Lymphocytes/immunology Cancer Vaccines/administration & dosage/*immunology DNA-Binding Proteins/*immunology Dendritic Cells/*immunology Epitopes Epitopes, T-Lymphocyte/*immunology Flow Cytometry Freund's Adjuvant/administration & dosage HLA-A Antigens/immunology Humans Interferon Type II/biosynthesis Lipids/administration & dosage Lymph Nodes/cytology Mice Mice, Transgenic Neoplasms, Experimental/*prevention & control Oligodeoxyribonucleotides/administration & dosage/*immunology Survival Analysis Telomerase/*immunology
Pubmed
Web of science
Création de la notice
25/01/2008 15:08
Dernière modification de la notice
20/08/2019 13:42
Données d'usage